Acute toxicity study of Mesenchymal Stromal cells derived from Wharton`s Jelly in mouse by intravenous and subcutaneous route
DOI:
https://doi.org/10.21276/IJRDPL.2278-0238.2017.6(5).2748-2756Keywords:
Wharton’s Jelly (WJ), Mesenchymal Stromal Cells (MSCs), Acute toxicity, Minimum Lethal Dose (MLD), Maximum Tolerance Dose (MTD)Abstract
Aim: The present study was to evaluate the acute toxicity of WJ-MSCs in mouse by intravenous and subcutaneous route and to assess their potential for side effects, MLD, MTD and LD50.
Objectives: Wide ranges of clinical and preclinical trials have suggested exploitation of adult MSCs for the cell-based reparative therapeutic approach; considering pros and cons of embryonic stem cells. However, for the clinical use existing adult stem cells source such as bone marrow, adipose tissue may be detrimental due to invasiveness in the procedure, less number of initial isolation and unsuitability for allogenic transplants. Recently fetal tissues such as Placenta, WJ have attracted as a good stem cell source due to its easy accessibility, ethical safety, immunological tolerance and large number of initial isolation of homogenous population necessary for increasing current market demand.
Methods: In present study, we tried to work on complete characterization and up-scaling profiling of cells isolated from WJ, along with assessment of possible toxic effects of these cells when administered in-vivo and optimizing the route of administration with other clinical evaluation been addressed.
Results: We confirmed that cells isolated from WJ exhibit morphologically and phenotypically similar properties as MSCs. The animal study also reveled that no mortality, no abnormal clinical signs and no remarkable pathological changes.
Conclusion: Our animal toxicity study along with attempted rapid expansion of these cells to meet large clinical demands would allow them to be a lucrative candidate for clinical therapy.
Downloads
References
Newman RE, Yoo D, LeRoux MA and Danilkovitch A. Treatment of inflammatory diseases with mesenchymal stem cells. Inflammation & Allergy Drug Targets.2009;8(2):110-123.[View in PubMed]
Semenov O.V and Breymann C. Mesenchymal Stem Cells Derived from Wharton’s Jelly and their Potential for Cardio-Vascular Tissue Engineering. The Open Tissue Engineering and Regenerative Medicine Journal.2011; 4:64-7.
Susanne Kern K, Hermann E, Johannes S, Harald K and Kare B. Comparative analysis of Mesenchymal Stem Cells from Bone marrow, Umbilical Cord Blood or Adipose tissue. Stem cell.2006; 24(5): 1294–1301.[View in PubMed]
Gotherstrom C, Ringden O, Westgren M, Tammik C and Blanc Le. Immunomodulatory effects of human foetal liver-derived mesenchymal stem cells. Bone Marrow Transplant. 2003; 32(3): 265-272.
Gude NM, Roberts CT, Kalionis B and King RG. Growth and function of the normal human placenta. Thrombosis Research. 2004; 114 (5-6): 397-407.
Benirschke K and Kaufmann P. “Pathology of the human placenta”, Springer Berlin 5th Edition, 2006.
Larsen WJ. “Human Embryology”. The developing human, Churchill Livingstone, Philadelphia, 8th edition, 2001.
Kobayashi K, Kubota T and Aso T. Study on myofibroblast differentiation in the stromal cells of Wharton's jelly: expression and localization of alpha-smooth muscle actin. Early Human Development.1998; 51(3): 223-33.
Solanki A, Kim JD, Lee KB. Nanotechnology for regenerative medicine: nanomaterials for stem cell imaging. Nanomedicine. 2008; 3(4):567-578.
Peiman H. Role of mesenchymal stromal cells in solid organ transplantation. Transplant Review.2008; 22(4): 262-273.
Williams AR and Hare JM. Mesenchymal stem cells: Biology, pathophysiology, translational findings and therapeutic implications for cardiac diseases. Circulation Research, 2011; 108 (8): 923-940.[View in PubMed]
Devang MP, Jainy S and Anand S. Therapeutic potential of Mesenchymal Stem Cells in Regenerative Medicines. Stem cell international. 2013; 2013:496218: 15.
Nekanti U, Mohanty L, Venugopal P, Balasubramanian S, Totey S and Ta. M. Optimization and scale up of Wharton’s jelly derived mesenchymal stem cells for clinical applications. Stem cell research.2010; 5(3): 244-254.
Jaianand K, Balaji P. Clinical Prospects of Scale-Up FoetalWhartons Jelly Derived Multipotent Stromal Cells to fulfil the Therapeutic Demands. Int J Pharm. Bio. Sci.2015; 06(4): 882-894.
Jaianand K, Balaji P. Isolation, Characterization and Scale-Up of Foetal Amniotic Membrane Derived Multipotent Stromal Cells for Therapeutic Applications. Int J Pharm. Bio. Sci. 2015; 06(2): 376-385.
Jaianand K, Shraddha SG. Effect of Antibiotics on Mesenchymal Stromal Cells under Xeno-free Culture Conditions for Clinical use. Int J Pharm. Bio. Sci. 2013; 04(4): 891-898.
Young Bang O, Jin SL, Hyu Lee and Gwang Lee. Autologous mesenchymal stem cell transplantation in stroke patients. Annals of Neurology. 2005; 57: 874–882.
Pal R, Venkataramana NK., Bansal A, Balaraju S, Jan M, Chandra R, Dixit A, Rauthan A, Murgod U and Totey S. Ex vivo-expanded autologous bone marrow-derived mesenchymal stromal cells in human spinal cord injury/paraplegia: a pilot clinical study. Cytotherapy. 2009; 11(7): 897-911.
Martino G, Franklin RJ, VanEvercooren AB and Kerr DA. Stem cells in multiple sclerosis (STEMS) consensus group. Stem cell transplantation in multiple sclerosis: current status and future prospects. Nature Reviews Neurology. 2010; 6 (5):247–255.
Freedman MS, Bar-Or A, Atkins HL. Karussis D, Frassoni F, Lazarus H, Scolding N, Slavin S, Le Blanc K, Uccelli A; MSCT Study Group. The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. Multiple Sclerosis. 2010; 16(4):503–510.
Wang D, Akiyama K, Zhang H., Yamaza T, Li X, Feng X, Wang H, Hua B, Liu B, Xu H, Chen W, Shi S and Sun L. Double allogenic mesenchymal stem cells transplantations could not enhance therapeutic effect compared with single transplantation in systemic lupus erythematosus. Clinical and Development Immunology. 2012; 2012:273291.
Reinders ME, de Fijter JW, Roelofs H, Bajema IM, de Vries DK, Schaapherder AF, Claas FH, van Miert PP, Roelen DL, van Kooten C, Fibbe WE and Rabelink TJ. Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: results of a phase I study. Stem Cells Translational Medicine. 2013; 2(2), 107-11.
Kim SJ, Moon GJ, Chang WH., Kim YH and O.Y. Bang. Intravenous transplantation of mesenchymal stem cells preconditioned with early phase stroke serum: current evidence and study protocol for a randomized trial. Stem cell Application Researches and Trials in Neurology. 2013; 14(1):317.
Published
How to Cite
Issue
Section
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
.